Stockreport

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB Biotherapeutics, Inc.  (SABS) 
PDF Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by t [Read more]